Toshihiko Nishiyama

发表

Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist.

H. Mitsuya, K. Maeda, H. Nakai, 2011, Bioorganic & medicinal chemistry.

Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite.

H. Mitsuya, K. Maeda, M. Toda, 2007, Bioorganic & medicinal chemistry letters.

Design and synthesis of orally bioavailable inhibitors of inducible nitric oxide synthase. Part 1: synthesis and biological evaluation of dihydropyridin-2-imines.

S. Kusuda, K. Hirai, M. Toda, 2002, Bioorganic & medicinal chemistry letters.

Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.

H. Mitsuya, K. Maeda, W. Kazmierski, 2011, Bioorganic & medicinal chemistry letters.

Discovery of orally available spirodiketopiperazine-based CCR5 antagonists.

H. Mitsuya, K. Maeda, K. Hirai, 2010, Bioorganic & medicinal chemistry.

Spirodiketopiperazine-based CCR5 antagonists: Improvement of their pharmacokinetic profiles.

H. Mitsuya, K. Maeda, K. Hirai, 2010, Bioorganic & medicinal chemistry letters.

Design and synthesis of orally bioavailable inhibitors of inducible nitric oxide synthase. synthesis and biological evaluation of dihydropyridin-2(1H)-imines and 1,5,6,7-tetrahydro-2H-azepin-2-imines.

S. Kusuda, K. Hirai, M. Toda, 2003, Bioorganic & medicinal chemistry.

Studies on novel and chiral 1,4-dihydropyridines. IV. Mechanistic aspects of the asymmetric reduction with chiral NADH model compounds, (SS)-3-(p-tolylsulfinyl)-1,4-dihydropyridines☆☆☆

K. Miyashita, S. Obika, T. Imanishi, 1997 .

Design and synthesis of orally bioavailable inhibitors of inducible nitric oxide synthase. Identification of 2-azabicyclo[4.1.0]heptan-3-imines.

S. Kusuda, K. Hirai, M. Toda, 2003, Bioorganic & medicinal chemistry.

Design and synthesis of inhibitors of inducible nitric oxide synthase. Discovery of a new chemical lead with potential for oral bioavailability.

S. Kusuda, K. Hirai, M. Toda, 2003, European journal of medicinal chemistry.

Studies on novel and chiral 1,4-dihydropyridines. III. Asymmetric reduction of some ketones with novel NADH model compounds, (SS)-3-(p-Tolylsulfinyl)-1,4-dihydropyridines

K. Miyashita, S. Obika, T. Imanishi, 1997 .

Stereospecific 4-Hydrogen Transfer in the Asymmetric Reduction Using (SS)-3-(p-Tolylsulfinyl)-1,4-dihydropyridines, NADH Model Compounds

K. Miyashita, S. Obika, T. Imanishi, 1996 .

Studies on Novel and Chiral 1, 4-Dihydropyridines. I. Synthesis and Conformational Analysis of Novel NADH Model Compounds, N-Substituted (S)-3-(p-Tolylsulfinyl)-1, 4-dihydropyridines

K. Miyashita, S. Obika, T. Imanishi, 1996 .

Discovery of new orally active prostaglandin D2 receptor antagonists.

M. Toda, H. Nakai, M. Iwahashi, 2011, Bioorganic & medicinal chemistry.

THE EGO-FUNCTIONING OF RELIGIOUS PERSONALITIES

Toshihiko Nishiyama, 1974 .